{
    "nct_id": "NCT05023980",
    "official_title": "A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "inclusion_criteria": "* Confirmed diagnosis of CLL/SLL requiring therapy, per iwCLL 2018 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Adequate organ function\n* Platelets greater than or equal to (≥)75 x 10⁹/liter (L) (≥50 × 10⁹/L for patients with evidence of bone marrow infiltrate), hemoglobin ≥8 grams/deciliter (g/dL), and absolute neutrophil count ≥0.75 x 10⁹/L\n* Kidney function: Estimated creatinine clearance ≥40 milliliters per minute (mL/min)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known or suspected Richter's transformation at any time preceding enrollment\n* Prior systemic therapy for CLL/SLL\n* Presence of 17p deletion\n* Central nervous system (CNS) involvement\n* Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP])\n* Significant cardiovascular disease\n* Active hepatitis B or hepatitis C\n* Active cytomegalovirus (CMV) infection\n* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count\n* Concurrent use of investigational agent or anticancer therapy except hormonal therapy\n* Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist\n* Vaccination with a live vaccine within 28 days prior to randomization\n* Patients with the following hypersensitivity:\n\n  * Known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib or bendamustine\n  * Prior significant hypersensitivity to rituximab",
    "miscellaneous_criteria": ""
}